Company intelligence / Profile preview

Aralez Pharmaceuticals

Mississauga, Ontario, Canadadhpp.hpfb-dgpsa.ca ↗

Ownership: Private
Development stage: Commercial

Overview

Aralez Pharmaceuticals was a global specialty pharmaceutical company formed from the merger of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., focusing on acquiring, developing, and commercializing products primarily in cardiovascular and other specialty areas. The company operated across North America and Europe with an anchor position in cardiovascular disease. It discontinued U.S. commercial operations as of 2018[1][5].

Therapeutic areas: OtherCardiovascularNeurology
Modalities: Small molecules (primarily; focus on cardiovascular and pain therapies)[1][5]
Industry: Biotech

Drug pipeline

3 assets

VIMOVO

Commercial

Indications: Pain, Arthritis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Aralez Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aralez Pharmaceuticals.

Explore the full profile